Is Celldex Therapeutics, Inc. (CLDX) a Buy? [The Motley Fool]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: The Motley Fool
The odds just might finally be in this biotech's favor. Many biotech stocks posted strong performances in 2017. Celldex Therapeutics ( NASDAQ:CLDX ) wasn't one of them. The clinical-stage biotech saw its share price drop 20% last year. And that's on top of losing nearly 80% of its market cap in 2016. But is Celldex a stock to buy with a new year under way? Here are the arguments for and against the beaten-down biotech stock. Image source: Getty Images. Reasons to stay away You won't have to look too hard to find a big reason not to buy Celldex stock: It's risky. Nothing illustrates this risk better than the huge clinical failure for the biotech's once-promising glioblastoma immunotherapy Rintega. And remember: Rintega had already cleared phase 1 and phase 2 hurdles and was in a late-stage study. None of Celldex's other current pipeline candidates are that far along in development. Another example of the risk associated with investing in Celldex stock is w
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria [Yahoo! Finance]Yahoo! Finance
- Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaGlobeNewswire
- Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.MarketBeat
- Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceGlobeNewswire
CLDX
Earnings
- 2/26/24 - Miss
CLDX
Sec Filings
- 3/1/24 - Form 8-K
- 3/1/24 - Form 424B5
- 2/28/24 - Form 424B5
- CLDX's page on the SEC website